MULTIPURPOSE PREVENTION TECHNOLOGIES (MPTs) FOR SEXUAL AND REPRODUCTIVE HEALTH: MEETING A CRITICAL NEED FOR WOMEN AND THEIR FAMILIES

Chairs: Bethany Young Holt (CAMI) & Manjula Lusti-Narasimhan (WHO)

24 May 2013
What are Multipurpose Prevention Technologies (MPTs)?

A single product, configured for at least two SRH prevention indications:

- **Unintended pregnancy**
- **HIV**
- **Other STIs**

**WHY MPTs?**

-Greater **efficiency** in terms of cost, access and delivery of SRH prevention products

- Capitalize on the demand in populations using one product type to achieve uptake and use of a second “product”
Initiative for Multipurpose Prevention Technologies (IMPT)

Scientific Agenda
Acceptability and Access
Communications, Advocacy and Outreach

Secretariat:
National & Int’l Agencies & Donors
Gates Foundation, ICMR, IPPF, USAID, USFDA, US National Institutes of Health, WHO, Wellcome Trust

Research & Public Health Orgs
California Family Health Council, CONRAD, IPM, Jhpiego, PATH, Population Council, Public Health Institute, RTI International

SRH Policy and Advocacy Orgs
AVAC, ARHP, Guttmacher Institute

Biotechnology Companies & Orgs
Auritec, Mapp Biopharmaceutical, Medicines360, Osel, ReProtect, Teva, WomanCare Global

Universities
China, India, Kenya, Nigeria, South Africa, UK, USA

part of the Public Health Institute
Session Format

What are MPTs and why do we need them?
Helen Rees
Wits Reproductive Health and HIV Institute,
University of Witwatersrand

MPTs available now and on the horizon
Wayne Shields
Association of Reproductive Health Professionals

Aligning investments in MPT R&D and the critical path to MPT introduction
Judy Manning
US Agency for International Development

Panel Discussion

Session Chairs: Bethany Young Holt (CAMI) & Manjula Lusi-Narasiham (WHO)